All In Biotech

Free tool

FAERS Monitor: Bafiertam

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210296 or its brand name (Bafiertam, Monomethyl Fumarate). Reports on generic versions are filed under their own applications.

Reports

935

Serious

127

14% of reports

Hospitalization

52

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • flushing350
  • pruritus110
  • product dose omission issue83
  • nausea76
  • abdominal discomfort65
  • erythema65
  • abdominal pain upper51
  • fatigue47
  • diarrhoea46
  • rash44
  • dizziness43
  • paraesthesia43
  • feeling hot41
  • headache40
  • multiple sclerosis relapse40

Reports by year received

View as table
YearReports
20191
20201
202173
2022227
2023166
2024318
2025110
202639

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,224 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
flushingSignal35077.771.526,463
feeling hotSignal4115.111.2525
multiple sclerosis relapseSignal4013.19.7438
abdominal discomfortSignal658.76.9440
erythemaSignal657.15.6339
pruritusSignal1106.45.4509
product dose omission issueSignal836.45.2374
paraesthesiaSignal436.14.6182
abdominal pain upperSignal515.64.3189
rashSignal442.31.731
nauseaSignal762.21.748
dizziness431.91.419
diarrhoea461.61.210
headache401.41.15
fatigue471.41.04

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.